Suppliers and packagers for generic pharmaceutical drug: CABOZANTINIB S-MALATE

CABOZANTINIB S-MALATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756	NDA	Exelixis, Inc.	42388-011-14	4 BLISTER PACK in 1 CARTON (42388-011-14) / 1 KIT in 1 BLISTER PACK	2012-11-29
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756	NDA	Exelixis, Inc.	42388-012-14	4 BLISTER PACK in 1 CARTON (42388-012-14) / 1 KIT in 1 BLISTER PACK	2012-11-29
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756	NDA	Exelixis, Inc.	42388-013-14	4 BLISTER PACK in 1 CARTON (42388-013-14) / 21 CAPSULE in 1 BLISTER PACK	2012-11-29
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692	NDA	Exelixis, Inc.	42388-023-26	30 TABLET in 1 BOTTLE (42388-023-26)	2016-04-25

CABOZANTINIB S-MALATE: KEY GLOBAL SUPPLIERS ANALYSIS

Last updated: February 19, 2026

This report identifies and analyzes key global suppliers of Cabozanitinib S-Malate, a tyrosine kinase inhibitor used in oncology. The analysis focuses on identifying manufacturers with established production capabilities, regulatory compliance, and capacity for supplying this complex Active Pharmaceutical Ingredient (API).

What is Cabozanitinib S-Malate?

Cabozanitinib S-Malate is the salt form of cabozantinib, a small molecule inhibitor targeting multiple receptor tyrosine kinases, including MET, VEGFRs, RET, KIT, AXL, and FLT3. These kinases are implicated in tumor growth, angiogenesis, metastasis, and drug resistance. The S-malate salt form is used to improve the solubility and bioavailability of cabozantinib, enhancing its therapeutic efficacy.

Cabozanitinib is approved for the treatment of:

• Medullary thyroid cancer
• Renal cell carcinoma
• Hepatocellular carcinoma
• Prostate cancer (in combination with other agents)

The synthesis of cabozanitinib is a multi-step process involving complex organic chemistry, requiring stringent quality control and adherence to Good Manufacturing Practices (GMP). The S-malate salt formation adds a further layer of complexity to its manufacturing and purification.

Global Landscape of Cabozanitinib S-Malate API Suppliers

The supply chain for Cabozanitinib S-Malate API is concentrated among a limited number of manufacturers capable of meeting the regulatory and technical demands of producing this specialized oncology drug. These suppliers are primarily located in Asia and Europe, leveraging established pharmaceutical manufacturing infrastructure and expertise.

The following table outlines key suppliers and their characteristics:

Supplier Name	Primary Location	Key Certifications/Compliance	Notes
LGM Pharma	United States	FDA Registered, DEA Licensed, ISO 9001:2015, cGMP	While a US-based distributor and services provider, LGM Pharma sources APIs globally and is a significant player in the US market for specialized oncology APIs, including Cabozanitinib S-Malate.
WuXi AppTec	China	FDA Inspected, EMA Approved, cGMP, ISO 13485, ISO 9001	A leading global contract research, development, and manufacturing organization (CRDMO) with extensive API manufacturing capabilities. Offers custom synthesis and large-scale production.
Boc Sciences	United States	cGMP	Specializes in custom synthesis and catalog chemicals for research and pharmaceutical industries. Offers various forms of cabozantinib and related intermediates.
Forchem AB	Sweden	ISO 9001:2015, cGMP	A supplier of fine chemicals and APIs. Their capabilities include complex synthesis and high-purity APIs.
Teva Pharmaceutical Industries Ltd.	Israel	FDA Approved, EMA Approved, cGMP, PIC/S GMP Guide	A major generic pharmaceutical manufacturer with significant API production capacity. Likely to produce cabozantinib S-Malate for its generic formulations.
Sun Pharmaceutical Industries Ltd.	India	FDA Inspected, EMA Approved, cGMP, WHO GMP	One of the largest generic pharmaceutical companies globally. Possesses substantial API manufacturing infrastructure in India and is a significant supplier of oncology APIs.
Dr. Reddy's Laboratories	India	FDA Inspected, EMA Approved, cGMP, WHO GMP	A prominent Indian pharmaceutical company with strong API development and manufacturing capabilities, including complex molecules for oncology.
Divi's Laboratories	India	FDA Inspected, EMA Approved, cGMP, ISO 9001:2015	A leading API manufacturer known for its large-scale production and cost-efficiency in complex API synthesis.
Cipla Limited	India	FDA Inspected, EMA Approved, cGMP, WHO GMP	A significant Indian pharmaceutical company with a broad portfolio of APIs, including oncology products.

Regulatory Filings and Compliance

For pharmaceutical companies seeking to secure a reliable supply of Cabozanitinib S-Malate API, understanding the regulatory compliance of potential suppliers is paramount. Key regulatory bodies whose approvals and inspections are critical include:

• U.S. Food and Drug Administration (FDA): Inspection of manufacturing facilities and review of Drug Master Files (DMFs) are essential for API suppliers to the US market.
• European Medicines Agency (EMA): Similar to the FDA, EMA requires GMP compliance and adherence to European Pharmacopoeia standards.
• Pharmaceutical Inspection Co-operation Scheme (PIC/S): Adherence to PIC/S GMP guidelines is a benchmark for global quality standards, recognized by numerous regulatory authorities.
• World Health Organization (WHO) GMP: Important for suppliers to emerging markets and for companies adhering to international health organization standards.

Suppliers must demonstrate a robust quality management system, with certifications such as ISO 9001:2015 indicating a commitment to overall quality processes.

Manufacturing Capacity and Scale

The production of Cabozanitinib S-Malate requires specialized reactors, advanced purification technologies (e.g., chromatography, crystallization), and robust analytical capabilities for impurity profiling and potency testing. Suppliers with demonstrated experience in producing high-potency APIs (HPAPIs) are generally better equipped to handle cabozantinib.

Key considerations for manufacturing capacity include:

• Batch Size: The ability to produce API in commercially viable batch sizes to meet global demand.
• Process Robustness: Proven consistency in API quality across multiple batches.
• Capacity Expansion: The potential for scaling up production in response to increased market demand.
• Supply Chain Security: The ability to manage raw material sourcing and prevent supply chain disruptions.

Companies like WuXi AppTec and Divi's Laboratories are known for their large-scale manufacturing capacities and have a proven track record in producing complex APIs, making them strong contenders for high-volume supply contracts.

Key Intermediates and Their Suppliers

The synthesis of cabozanitinib involves several key intermediates. The availability and quality of these precursors directly impact the efficiency and cost-effectiveness of the final API production. While detailed synthetic routes are proprietary, common chemical building blocks and advanced intermediates are crucial.

Generic intermediates for cabozanitinib synthesis may include:

• 4-Chloro-7-methoxyquinazoline: A core quinazoline scaffold.
• 2-Fluoro-4-trifluoromethylaniline: A key aromatic amine component.
• 1-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-3-(4-fluoro-2-methylphenyl)urea: This is closer to the final cabozantinib molecule, but intermediates leading to its formation are critical.

Specialty chemical suppliers and Contract Manufacturing Organizations (CMOs) often produce these intermediates. Companies that offer custom synthesis services for these complex organic molecules are vital to the cabozanitinib supply chain.

Intermediate Category	Potential Supplier Types
Basic Chemical Feedstocks	Large-scale chemical manufacturers, bulk chemical distributors.
Advanced Organic Intermediates	Specialized custom synthesis providers, fine chemical manufacturers with expertise in heterocyclic chemistry and fluorination.
Chiral Resolving Agents/Catalysts	Companies specializing in chiral chemistry and catalysis, crucial for obtaining the desired S-malate salt purity.

Suppliers of intermediates must also adhere to GMP standards, particularly for late-stage intermediates, to ensure the quality and safety of the final API. Auditing intermediate suppliers is a critical due diligence step for API manufacturers.

Challenges in Cabozanitinib S-Malate Supply

The procurement of Cabozanitinib S-Malate API is subject to several challenges:

1. Complexity of Synthesis: The multi-step synthesis involves challenging organic reactions, requiring specialized equipment and skilled personnel. This limits the number of manufacturers capable of consistent, high-quality production.
2. Regulatory Hurdles: Meeting stringent GMP requirements and obtaining approvals from regulatory bodies like the FDA and EMA is a lengthy and costly process.
3. Impurity Control: Identifying, characterizing, and controlling process-related impurities and degradation products is critical for patient safety. This requires sophisticated analytical techniques and rigorous process validation.
4. Intellectual Property: While the primary patents for cabozantinib may have expired or are nearing expiry in certain regions, process patents and polymorph patents can still influence market access and supplier choices.
5. Raw Material Sourcing: Secure and consistent sourcing of critical raw materials and intermediates is essential. Disruptions in the supply of these precursors can impact API production timelines.
6. Scale-Up Issues: Transitioning from laboratory-scale synthesis to commercial-scale manufacturing often presents unforeseen challenges in terms of yield, purity, and process robustness.
7. Geopolitical Factors: Global supply chains can be affected by trade policies, tariffs, and geopolitical stability, particularly for APIs manufactured in specific regions.

Strategic Sourcing Considerations

Pharmaceutical companies and investors evaluating the Cabozanitinib S-Malate market should consider the following strategic sourcing factors:

• Supplier Due Diligence: Conduct thorough audits of potential suppliers' manufacturing facilities, quality management systems, regulatory compliance history, and financial stability.
• Quality Agreements: Establish comprehensive quality agreements that clearly define roles, responsibilities, specifications, change control procedures, and batch release requirements.
• Dual Sourcing Strategy: To mitigate supply chain risks, consider establishing relationships with at least two qualified API suppliers. This provides redundancy in case of production issues, regulatory actions, or unforeseen events at one supplier.
• Long-Term Contracts: Secure long-term supply agreements to ensure price stability and guaranteed supply volumes, especially for critical oncology drugs.
• Geographic Diversification: When possible, diversify sourcing across different geographic regions to reduce reliance on any single country or region, mitigating geopolitical and logistical risks.
• Intellectual Property Landscape: Thoroughly research the IP landscape, including process patents, to understand potential freedom-to-operate issues for generic manufacturers and to assess the innovative capabilities of API suppliers.
• Cost Analysis: While quality and regulatory compliance are paramount, perform a comprehensive cost analysis that includes API pricing, shipping, import duties, quality assurance overhead, and inventory holding costs.

Key Takeaways

• The global supply of Cabozanitinib S-Malate API is concentrated among a select group of manufacturers with advanced synthetic chemistry capabilities and robust regulatory compliance.
• Key suppliers are primarily located in China and India, alongside specialized providers in the US and Europe, all adhering to cGMP standards and subject to FDA and EMA scrutiny.
• A dual sourcing strategy, coupled with thorough supplier due diligence and comprehensive quality agreements, is essential for ensuring reliable and compliant API procurement.
• Challenges in synthesis, impurity control, and regulatory compliance necessitate a deep understanding of manufacturing processes and quality management systems by all supply chain participants.
• Monitoring the intellectual property landscape and geopolitical factors is crucial for long-term supply chain stability and strategic decision-making.

FAQs

1. What are the primary regulatory requirements for Cabozanitinib S-Malate API suppliers? Suppliers must adhere to Current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes robust quality management systems, validated manufacturing processes, comprehensive impurity profiling, and the ability to file Drug Master Files (DMFs) or equivalent documentation.

2. How can a pharmaceutical company ensure the quality of Cabozanitinib S-Malate API from a new supplier? Ensuring quality involves a multi-faceted approach: conducting thorough on-site audits of manufacturing facilities and quality control laboratories, reviewing supplier quality agreements, requesting and scrutinizing Certificates of Analysis (CoAs) for multiple batches, and performing independent analytical testing of incoming API batches.

3. What is the significance of S-Malate salt in Cabozanitinib production? The S-Malate salt form is crucial for enhancing the solubility and bioavailability of cabozanitinib. The formation and purification of this specific salt require precise control over crystallization conditions to achieve the desired polymorphic form and purity, adding complexity to the API manufacturing process.

4. Are there any major supply chain risks associated with sourcing Cabozanitinib S-Malate from a single supplier? Yes, relying on a single supplier introduces significant risks, including production disruptions due to equipment failure, quality issues, regulatory actions against the supplier, raw material shortages, or geopolitical instability impacting that supplier's region. A dual sourcing strategy mitigates these risks.

5. How do intellectual property considerations impact the supply of Cabozanitinib S-Malate? While the primary composition of matter patents for cabozanitinib may have expired, secondary patents related to specific manufacturing processes, polymorphs, or salt forms can still influence market entry for generic API manufacturers. Understanding this IP landscape is critical for ensuring freedom to operate and for assessing the proprietary advantages of certain API suppliers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-file-system/drug-master-files-dmfs [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-manufacturing-practice-gmp [3] Pharmaceutical Inspection Co-operation Scheme. (n.d.). PIC/S GMP Guide. Retrieved from https://picscheme.org/en/Gmp-guidance [4] World Health Organization. (n.d.). WHO Good manufacturing practices (GMP) for pharmaceutical products. Retrieved from https://www.who.int/teams/regulation-quality-safety/policy-and-strategy/good-manufacturing-practice [5] ISO 9001:2015. (2015). Quality management systems – Requirements. International Organization for Standardization. [6] LGM Pharma. (n.d.). API Sourcing Solutions. Retrieved from https://www.lgmpharma.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [7] WuXi AppTec. (n.d.). API Development and Manufacturing. Retrieved from https://www.wuxiapptec.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [8] Boc Sciences. (n.d.). API Manufacturing Services. Retrieved from https://www.bocsci.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [9] Forchem AB. (n.d.). Products & Services. Retrieved from https://www.forchem.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [10] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from https://www.tevapharm.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [11] Sun Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from https://www.sunpharma.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [12] Dr. Reddy's Laboratories. (n.d.). APIs. Retrieved from https://www.drreddys.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [13] Divi's Laboratories. (n.d.). APIs. Retrieved from https://www.divislabs.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [14] Cipla Limited. (n.d.). APIs. Retrieved from https://www.cipla.com/ (Note: Specific product availability is typically not public; accessed for general company profile and services.) [15] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/ (Accessed for general IP landscape research methodologies.) [16] European Patent Office. (n.d.). Espacenet. Retrieved from https://worldwide.espacenet.com/ (Accessed for general IP landscape research methodologies.)